44Sc: An attractive isotope for peptide-based PET imaging

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2954-2961

  Hernandez, Reinier ^a   Valdovinos, Hector F ^a   Yang, Yunan ^b   Chakravarty, Rubel ^b,c   Hong, Hao ^b   Barnhart, Todd E ^a   Cai, Weibo ^a,b,d  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c BHABHA ATOMIC RESEARCH CENTRE   (India)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

arginine glycine aspartic acid (RGD) peptides; molecular imaging; positron emission tomography (PET); RGD dimer; tumor angiogenesis

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; CALCIUM ION; COPPER 64; GALLIUM 68; RADIOISOTOPE; SCANDIUM 44; TETRAXETAN; TRACER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; 1,4,7,10-TETRAAZACYCLODODECANE- 1,4,7,10-TETRAACETIC ACID; ARGINYL-GLYCYL-ASPARTIC ACID; CALCIUM; OLIGOPEPTIDE; PEPTIDE; SCANDIUM; SINGLE HETEROCYCLIC RINGS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER MODEL; CHROMATOGRAPHY; CYCLOTRON; DRUG DISTRIBUTION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; KIDNEY CLEARANCE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON RADIATION; RADIOACTIVITY; RECEPTOR BLOCKING; TISSUE DISTRIBUTION; TUMOR XENOGRAFT; ANIMAL; BINDING COMPETITION; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE MODEL; IC50; IMAGE PROCESSING; METABOLISM; MOLECULAR IMAGING; NEOPLASM; PROCEDURES; PROTEIN MOTIF; TUMOR CELL LINE; VASCULARIZATION;

AMINO ACID MOTIFS; ANIMALS; BINDING, COMPETITIVE; CALCIUM; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; INHIBITORY CONCENTRATION 50; INTEGRIN ALPHAVBETA3; MICE; MOLECULAR IMAGING; NEOPLASM TRANSPLANTATION; NEOPLASMS; OLIGOPEPTIDES; PEPTIDES; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; SCANDIUM; TISSUE DISTRIBUTION;

EID: 84905502164     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500343j     Document Type: Article

References (39)

1. Allen, E.; Walters, I. B.; Hanahan, D. Brivanib, a dual FGF/VEGF inhibitor, is active both first and second line against mouse pancreatic neuroendocrine tumors developing adaptive/evasive resistance to VEGF inhibition Clin. Cancer Res. 2011, 17, 5299-310
2. Folkman, J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis N. Engl. J. Med. 1995, 333, 1757-63
3. Ferrara, N. Vascular endothelial growth factor and the regulation of angiogenesis Recent Prog. Horm. Res. 2000, 55, 15-35 discussion 35-6.
4. 68Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging Eur. J. Nucl. Med. Mol. Imaging 2009, 36, 947-57
5. Hanahan, D.; Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis Cell 1996, 86, 353-64
6. Li, Z. B.; Cai, W.; Cao, Q.; Chen, K.; Wu, Z.; He, L.; Chen, X. (64)Cu-labeled tetrameric and octameric RGD peptides for small-animal PET of tumor alpha(v)beta(3) integrin expression J. Nucl. Med. 2007, 48, 1162-71
7. Puduvalli, V. K. Inhibition of angiogenesis as a therapeutic strategy against brain tumors Cancer Treat. Res. 2004, 117, 307-36
8. Sengupta, S.; Chattopadhyay, N.; Mitra, A.; Ray, S.; Dasgupta, S.; Chatterjee, A. Role of alphavbeta3 integrin receptors in breast tumor J. Exp. Clin. Cancer Res. 2001, 20, 585-90
9. Felding-Habermann, B.; Fransvea, E.; OToole, T. E.; Manzuk, L.; Faha, B.; Hensler, M. Involvement of tumor cell integrin alphavbeta3 in hematogenous metastasis of human melanoma cells Clin. Exp. Metastasis 2002, 19, 427-36
10. Bello, L.; Francolini, M.; Marthyn, P.; Zhang, J.; Carroll, R. S.; Nikas, D. C.; Strasser, J. F.; Villani, R.; Cheresh, D. A.; Black, P. M. Alphavbeta3 and alphavbeta5 integrin expression in glioma periphery Neurosurgery 2001, 49, 380-9 discussion 390.
11. Jin, H.; Varner, J. Integrins: roles in cancer development and as treatment targets Br. J. Cancer 2004, 90, 561-5
12. Kumar, C. C. Integrin alphavbeta3 as a therapeutic target for blocking tumor-induced angiogenesis Curr. Drug Targets 2003, 4, 123-31
13. Kumar, C. C.; Armstrong, L.; Yin, Z.; Malkowski, M.; Maxwell, E.; Ling, H.; Yaremko, B.; Liu, M.; Varner, J.; Smith, E. M.; Neustadt, B.; Nechuta, T. Targeting integrins alpha v beta 3 and alphavbeta5 for blocking tumor-induced angiogenesis Adv. Exp. Med. Biol. 2000, 476, 169-80
14. 68Ga-labelled mono-, di- and tetrameric RGD peptides Eur. J. Nucl. Med. Mol. Imaging 2011, 38, 128-37
15. Cai, W.; Wu, Y.; Chen, K.; Cao, Q.; Tice, D. A.; Chen, X. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alphavbeta3 Cancer Res. 2006, 66, 9673-81
16. Plow, E. F.; Haas, T. A.; Zhang, L.; Loftus, J.; Smith, J. W. Ligand binding to integrins J. Biol. Chem. 2000, 275, 21785-8
17. Terry, S. Y.; Abiraj, K.; Frielink, C.; van Dijk, L. K.; Bussink, J.; Oyen, W. J.; Boerman, O. C. Imaging integrin alphavbeta3 on blood vessels with 111In-RGD2 in head and neck tumor xenografts J. Nucl. Med. 2014, 55, 281-6
18. Trajkovic-Arsic, M.; Mohajerani, P.; Sarantopoulos, A.; Kalideris, E.; Steiger, K.; Esposito, I.; Ma, X.; Themelis, G.; Burton, N.; Michalski, C. W.; Kleeff, J.; Stangl, S.; Beer, A. J.; Pohle, K.; Wester, H. J.; Schmid, R. M.; Braren, R.; Ntziachristos, V.; Siveke, J. T. Multimodal molecular imaging of integrin alphavbeta3 for in vivo detection of pancreatic cancer J. Nucl. Med. 2014, 55, 446-51
19. Haubner, R.; Wester, H. J.; Burkhart, F.; Senekowitsch-Schmidtke, R.; Weber, W.; Goodman, S. L.; Kessler, H.; Schwaiger, M. Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics J. Nucl. Med. 2001, 42, 326-36
20. Haubner, R.; Wester, H. J.; Weber, W. A.; Mang, C.; Ziegler, S. I.; Goodman, S. L.; Senekowitsch-Schmidtke, R.; Kessler, H.; Schwaiger, M. Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography Cancer Res. 2001, 61, 1781-5
21. Beer, A. J.; Haubner, R.; Sarbia, M.; Goebel, M.; Luderschmidt, S.; Grosu, A. L.; Schnell, O.; Niemeyer, M.; Kessler, H.; Wester, H. J.; Weber, W. A.; Schwaiger, M. Positron emission tomography using [18F]Galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man Clin. Cancer Res. 2006, 12, 3942-9
22. Kenny, L. M.; Coombes, R. C.; Oulie, I.; Contractor, K. B.; Miller, M.; Spinks, T. J.; McParland, B.; Cohen, P. S.; Hui, A. M.; Palmieri, C.; Osman, S.; Glaser, M.; Turton, D.; Al-Nahhas, A.; Aboagye, E. O. Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients J. Nucl. Med. 2008, 49, 879-86
23. Breeman, W. A.; de Blois, E.; Sze Chan, H.; Konijnenberg, M.; Kwekkeboom, D. J.; Krenning, E. P. (68)Ga-labeled DOTA-peptides and (68)Ga-labeled radiopharmaceuticals for positron emission tomography: current status of research, clinical applications, and future perspectives Semin. Nucl. Med. 2011, 41, 314-21
24. 68Ga radiopharmaceutical chemistry Curr. Top. Med. Chem. 2010, 10, 1633-68
25. Anderson, C. J.; Ferdani, R. Copper-64 radiopharmaceuticals for PET imaging of cancer: Advances in preclinical and clinical research Cancer Biother. Radiopharm. 2009, 24, 379-393
26. Kolsky, K. L.; Joshi, V.; Mausner, L. F.; Srivastava, S. C. Radiochemical purification of no-carrier-added scandium-47 for radioimmunotherapy Appl. Radiat. Isot. 1998, 49, 1541-9
27. 44Sc a potential radionuclide for PET? Appl. Radiat. Isot. 2012, 70, 2669-76
28. 44Sc-based PET-radiopharmaceuticals Radiochim. Acta 2010, 98, 149-156
29. 44gSc from natural calcium Appl. Radiat. Isot. 2012, 70, 1526-30
30. Muller, C.; Bunka, M.; Reber, J.; Fischer, C.; Zhernosekov, K.; Turler, A.; Schibli, R. Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent beta - emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate J. Nucl. Med. 2013, 54, 2168-74
31. Wu, Y.; Zhang, X.; Xiong, Z.; Cheng, Z.; Fisher, D. R.; Liu, S.; Gambhir, S. S.; Chen, X. microPET imaging of glioma integrin alphavbeta3 expression using (64)Cu-labeled tetrameric RGD peptide J. Nucl. Med. 2005, 46, 1707-18
32. Valdovinos, H. F.; Hernandez, R.; Barnhart, T. E.; Cai, W.; Nickles, R. J. Unpublished work. University of Wisconsin, Madison, WI, 2014.
33. Max, R.; Gerritsen, R. R.; Nooijen, P. T.; Goodman, S. L.; Sutter, A.; Keilholz, U.; Ruiter, D. J.; De Waal, R. M. Immunohistochemical analysis of integrin alphavbeta3 expression on tumor-associated vessels of human carcinomas Int. J. Cancer. 1997, 71, 320-4
34. Wu, Z.; Li, Z. B.; Chen, K.; Cai, W.; He, L.; Chin, F. T.; Li, F.; Chen, X. microPET of tumor integrin alphavbeta3 expression using 18F-labeled PEGylated tetrameric RGD peptide (18F-FPRGD4) J. Nucl. Med. 2007, 48, 1536-44
35. Cai, W.; Niu, G.; Chen, X. Imaging of integrins as biomarkers for tumor angiogenesis Curr. Pharm. Des. 2008, 14, 2943-73
36. 44gSc production using a water target on a 13MeV cyclotron Nucl. Med. Biol. 2014, 41, 401-6
37. Majkowska-Pilip, A.; Bilewicz, A. Macrocyclic complexes of scandium radionuclides as precursors for diagnostic and therapeutic radiopharmaceuticals J. Inorg. Biochem. 2011, 105, 313-20
38. Cai, W.; Chen, X. Multimodality molecular imaging of tumor angiogenesis J. Nucl. Med. 2008, 49 (Suppl 2) 113S-28S
39. Shi, J.; Kim, Y. S.; Zhai, S.; Liu, Z.; Chen, X.; Liu, S. Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers Bioconjugate Chem. 2009, 20, 750-9